ray i ...

站在生物医药创新的前沿，细胞和基因治疗（CGT）行业有着非常高的技术壁垒，但总有一些企业凭借 坚定的战略定力和强大的技术实力，穿越行业周期，实现跨越式发展。 作为登陆科创板的CGT第一股，和元生物深耕细胞与基因治疗领域十余年，自主研发形成细胞和基因治 疗载体开发技术、细胞和基因治疗载体生产工艺及质控技术两大核心技术集群，布局了前沿的质粒、免 疫细胞、干细胞、病毒、mRNA、外泌体等相关的技术和工艺，从基础底层技术和产业化技术层面解决 瓶颈问题。 "和元生物的发展始终跟随中国生物医药产业从'跟跑'到'领跑'的时代步伐，逐步成长为细分行业领军 者。"和元生物董事长兼总经理潘讴东在接受中国证券报记者采访时表示，展望未来，依托国家和地方 对细胞和基因治疗这一重点发展方向持续的政策支持，公司临港产业基地产能将进一步爬坡释放。和元 生物将拓展布局再生医学领域，不断提升自身竞争力和市场渗透率，努力打造以细胞和基因治疗为核心 的国际产业化集团。 持续加强技术创新 和元生物成立于2013年，专注于为细胞和基因治疗领域的先导研究和药物研发提供一体化CRO（合同 研究组织）/CDMO（合同研发与生产组织）服务。 面对细胞与基因治疗 ...

和元生物成立于2013年，专注于为细胞和基因治疗领域的先导研究和药物研发提供一体化CRO（合同 研究组织）/CDMO（合同研发与生产组织）服务。 面对细胞与基因治疗研发的高技术门槛，和元生物持续深化技术创新。"CRO/CDMO企业竞争力主要体 现在核心技术能力、GMP平台实力、项目管理能力等多个方面。"潘讴东告诉记者，"自2006年投身创 业以来，二十年来我始终专注于细胞与基因治疗领域，亲历并推动着这一前沿赛道的技术创新。" "以病毒载体为例，其是CGT药物的重要载体。在病毒载体方面，我们的工艺技术在国际上已经达到了 领先水平。"潘讴东介绍。据了解，目前公司拥有包括分子生物学平台、实验级病毒载体包装平台、细 胞功能研究平台、SPF级动物实验平台、基因载体和细胞治疗工艺开发平台等全面的细胞和基因治疗 CRO/CDMO技术平台，在载体开发、病毒包装等关键环节具备领先的研发能力。 站在生物医药创新的前沿，细胞和基因治疗（CGT）行业有着非常高的技术壁垒，但总有一些企业凭借 坚定的战略定力和强大的技术实力，穿越行业周期，实现跨越式发展。 作为登陆科创板的CGT第一股，和元生物深耕细胞与基因治疗领域十余年，自主研发形成 ...

和元生物临港产业基地 公司供图 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) | 成交金额(万元) | 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-16 | 和辉光电 | 688238 | 2.62 | 1637.5 | 625 | 机构专用 | 国泰海通证券股份 | | | 2025-12-16 | 和辉光电 | 688238 | 2.62 | 1637.5 | 625 | 为营证套整合氢限 250 | 国泰海通证券股份 | | 12月16日，和辉光电大宗交易成交1250万股，成交额3275万元，占当日总成交额的19.7%，成交价2.62元，较市场收盘价2.64元折价0.76%。 ...

（上接1版） 圆桌座谈环节由中国科学技术大学科技商学院、管理学院执行院长叶强主持。芯原股份董事长戴伟民、 华恒生物董事长郭恒华、拓荆科技董事长吕光泉、利元亨创始人卢家红、和元生物董事长潘讴东、罗曼 股份董事长孙凯君、太力科技董事长石正兵等企业家参与座谈，分享了在强化核心技术攻关、优化公司 治理结构、利用资本市场工具实现跨越式发展等方面的经验与思考。 良好的生态离不开科技创新的源头活水。中国科学技术大学党委常委、副校长傅尧表示，中国科大以制 度创新为先导，率先探索并构建"赋权+转让+约定收益"为核心的科技成果转化新模式；以资本为纽 带，构建"教育—研发—孵化—投资"全链条创新创业生态，推动科技、产业、资本深度融合。中国科大 将继续发挥基础研究深厚、学科交叉融合的优势，聚焦集成电路、人工智能、量子科技、新能源、新材 料等前沿领域，打造更多原始创新成果，并推动其走向"从1到100"的产业化突破，共同构建"资本赋能 科创、科创引领产业"的良性生态，为发展新质生产力、推动高质量发展注入更强的"科大动能"。 中介机构是连接资本与实体经济的桥梁，是市场生态中不可或缺的专业力量。华安证券党委书记、董事 长章宏韬表示，"十四五 ...

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

证券日报网讯和元生物11月24日在互动平台回答投资者提问时表示，公司按照交易所的规定将在定期报 告中及时披露相应时点的股东数量。 ...

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

Core Insights - The company focuses on providing CRO and CDMO services for cell and gene therapy, as well as technical services in regenerative medicine and anti-aging fields [1][5][6] Financial Performance - For the period from January to September 2025, the company achieved a total revenue of 180 million yuan, a decrease of 1.91% year-on-year [1] - The CRO business generated revenue of 61.997 million yuan, reflecting a growth of 2.81% year-on-year, while the CDMO business revenue was 96.7021 million yuan, down 9.72% year-on-year [1] - Other main businesses, including research reagents and cell storage services, saw a revenue increase of 55.99%, totaling 21.3862 million yuan [1][2] Profitability - The company reported a net profit attributable to the parent company of -162 million yuan, which is a reduction in losses by 38.1258 million yuan compared to the same period last year [2] Business Development - The company has established over 14,700 collaborative research laboratories in the CRO sector and has completed over 600 CDMO projects, including five Phase III clinical projects [2] - The company has assisted clients in obtaining 60 clinical trial approvals, including 14 from the FDA [2] International Expansion - The company is expanding its CRO, CDMO, and regenerative medicine services overseas, utilizing online marketing and participation in influential academic conferences to enhance brand visibility [3] - A subsidiary has successfully registered Human Fibroblast Extracellular Vesicles with INCI, marking a significant milestone for global cosmetic market entry [3] Technological Advancements - The company is focusing on two core technology clusters and is exploring the application potential of emerging technologies in client projects [4] - AI technology is being integrated to enhance research efficiency and foster innovation through external collaborations [4] Market Trends - The company views the restructuring of domestic medical enterprises as a necessary step towards high-quality industry development, presenting new growth opportunities [5] - The company aims to leverage its extensive technical expertise and production capacity to meet the evolving market demands [5][6]